Literature DB >> 7999057

Obese Zucker (fa/fa) rats are resistant to insulin's inhibitory effect on hepatic apo B secretion.

J D Sparks1, C E Sparks.   

Abstract

Hepatocytes derived from lean Zucker rats have reduced secretion of apo B and lowered cellular apo B in response to a physiologic range of insulin (0.1 nM-10 nM). Effects are attenuated in hepatocytes derived from Zucker obese rats and seen only at higher insulin concentrations (> 100 nM) with a significant shifting of the dose-response curve. Decreased sensitivity and responsiveness of hepatocytes derived from obese rats suggests insulin resistance and dose-response curves are consistent with coexistent binding and post-binding defects. Inability to inhibit hepatic apo B secretion in the presence of short-term high levels of insulin may have important implications to the balance of intestinal and hepatic triglyceride-rich lipoprotein secretion post-prandially.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7999057     DOI: 10.1006/bbrc.1994.2681

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

Review 1.  Surgical risk in patients with metabolic syndrome: focus on lipids and hypertension.

Authors:  Karol Watson
Journal:  Curr Cardiol Rep       Date:  2006-11       Impact factor: 2.931

2.  Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus.

Authors:  Kazunori Nagashima; Carlos Lopez; Daniel Donovan; Colleen Ngai; Nelson Fontanez; André Bensadoun; Jamila Fruchart-Najib; Steve Holleran; Jeffrey S Cohn; Rajasekhar Ramakrishnan; Henry N Ginsberg
Journal:  J Clin Invest       Date:  2005-04-01       Impact factor: 14.808

3.  Apolipoprotein B mRNA editing and apolipoprotein gene expression in the liver of hyperinsulinemic fatty Zucker rats: relationship to very low density lipoprotein composition.

Authors:  M B Elam; M A von Wronski; L Cagen; F Thorngate; P Kumar; M Heimberg; H G Wilcox
Journal:  Lipids       Date:  1999-08       Impact factor: 1.880

4.  Chronic exogenous hyperinsulinaemia does not modify the acute inhibitory effect of insulin on the secretion of very-low-density lipoprotein triacylglycerol and apolipoprotein B in primary cultures of rat hepatocytes.

Authors:  C S Bourgeois; D Wiggins; G F Gibbons
Journal:  Biochem J       Date:  1996-02-15       Impact factor: 3.857

5.  Up-regulation of stearoyl-CoA desaturase 1 increases liver MUFA content in obese Zucker but not Goto-Kakizaki rats.

Authors:  Minako Karahashi; Fumiko Ishii; Tohru Yamazaki; Koichi Imai; Atsushi Mitsumoto; Yoichi Kawashima; Naomi Kudo
Journal:  Lipids       Date:  2013-03-29       Impact factor: 1.880

6.  Insulin dependent apolipoprotein B degradation and phosphatidylinositide 3-kinase activation with microsomal translocation are restored in McArdle RH7777 cells following serum deprivation.

Authors:  Janet D Sparks; Amy L Magra; Jeffrey M Chamberlain; Colleen O'Dell; Charles E Sparks
Journal:  Biochem Biophys Res Commun       Date:  2015-11-23       Impact factor: 3.575

7.  Insulin acutely inhibits intestinal lipoprotein secretion in humans in part by suppressing plasma free fatty acids.

Authors:  Mirjana Pavlic; Changting Xiao; Linda Szeto; Bruce W Patterson; Gary F Lewis
Journal:  Diabetes       Date:  2009-12-22       Impact factor: 9.461

8.  Insulin suppression of apolipoprotein B in McArdle RH7777 cells involves increased sortilin 1 interaction and lysosomal targeting.

Authors:  Jeffrey M Chamberlain; Colleen O'Dell; Charles E Sparks; Janet D Sparks
Journal:  Biochem Biophys Res Commun       Date:  2012-11-15       Impact factor: 3.575

9.  Insulin-mediated inhibition of apolipoprotein B secretion requires an intracellular trafficking event and phosphatidylinositol 3-kinase activation: studies with brefeldin A and wortmannin in primary cultures of rat hepatocytes.

Authors:  J D Sparks; T L Phung; M Bolognino; C E Sparks
Journal:  Biochem J       Date:  1996-01-15       Impact factor: 3.857

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.